Literature DB >> 2453556

Regulation of class II MHC molecules on human endothelial cells. Effects of IFN and dexamethasone.

C L Manyak1, H Tse, P Fischer, L Coker, N H Sigal, G C Koo.   

Abstract

Human vascular endothelial cells normally do not express class II MHC molecules in culture. IFN-gamma has been shown to induce expression of class I and class II MHC molecules on endothelial cell cultures from umbilical cord. We could detect these Ag by FACS analysis when endothelial cells were cultured for 3 days in the presence of 200 to 1000 U/ml of rIFN-gamma. Among the class II MHC molecules, HLA-DR and -DP but not -DQ were consistently induced. Addition of rIFN-alpha-D/A to IFN-gamma-treated cells inhibited the expression of class II MHC but not class I MHC molecules. Furthermore, the inhibition was more pronounced when IFN-alpha-D/A was added before or simultaneously as IFN-gamma. Natural IFN-alpha also exhibited similar inhibition and its suppressive effect was abolished in the presence of anti-IFN-alpha antibody. On the contrary, dexamethasone, a known inhibitor of class II MHC molecules on murine macrophages, showed a slight enhancing effect on class II MHC Ag. These results suggest an immunoregulatory role for IFN-alpha on non-lymphoid cells and that controlling elements for expression of class II MHC molecules may be different on various cell types as well as species.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453556

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Inhibition of delayed hypersensitivity reactions by colchicine. II. Colchicine inhibits interferon-gamma induced expression of HLA-DR on gut epithelial cell line.

Authors:  Y A Mekori; Y Chowers; I Ducker; A Klajman
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Different microvascular endothelial cell phenotypes exhibit different class I and II antigens under interferon-gamma.

Authors:  K Spanel-Borowski; G Bein
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-08       Impact factor: 2.416

3.  Induction of MHC class II antigen in cultured bovine ciliary epithelial cells.

Authors:  H Helbig; R C Gurley; R J Reichl; R Mahdi; R B Nussenblatt; A G Palestine
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

4.  Differential regulation of expression of the MHC class II molecules RT1.B and RT1.D on rat B lymphocytes: effects of interleukin-4, interleukin-13 and interferon-gamma.

Authors:  A Roos; E J Schilder-Tol; M A Chand; N Claessen; F G Lakkis; D W Pascual; J J Weening; J Aten
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

5.  Isotype-specific regulation of MHC class II gene expression in human monocytes by exogenous and endogenous tumor necrosis factor.

Authors:  M Jasiński; J Wieckiewicz; I Ruggiero; A Pituch-Noworolska; M Zembala
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

6.  Lipopolysaccharide augments HLA-A,B,C molecule expression but inhibits interferon-gamma-induced HLA-DR molecule expression on cultured human endothelial cells.

Authors:  A Otsuka; T Hanafusa; N Kono; S Tarui
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

7.  In the presence of dexamethasone, gamma interferon induces rat oligodendrocytes to express major histocompatibility complex class II molecules.

Authors:  K Bergsteindottir; A Brennan; K R Jessen; R Mirsky
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 8.  The potential role of interferons and interferon antagonists in inflammatory disease.

Authors:  H Heremans; A Billiau
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

9.  MHC antigen induction by interferon gamma on cultured mouse pancreatic beta cells and macrophages. Genetic analysis of strain differences and discovery of an "occult" class I-like antigen in NOD/Lt mice.

Authors:  E H Leiter; G J Christianson; D V Serreze; A T Ting; S M Worthen
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.